Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy
Patients older than ≥18 years, with muscle-invasive bladder cancer unfit for radical cystectomy because of age, comorbidities, and/or patient's refusal.

This study is designed as a multicentre, single-arm phase II study.
Bladder Cancer
DRUG: Atezolizumab
Disease Free Survival, Disease Free Survival is defined as the delay between date of inclusion and tumour relapse (local, regional, or distant) or death from any cause, whichever occurs first., 2 years
Local control rate, Local control rate will be evaluated by cystoscopy. The presence of non-muscle-invasive or muscle-invasive bladder cancers will be considered as a local failure. To be defined as locally controlled, the bladder must be completely free of tumour., 2 years|Local control rate, Local control rate will be evaluated by cystoscopy. The presence of non-muscle-invasive or muscle-invasive bladder cancers will be considered as a local failure. To be defined as locally controlled, the bladder must be completely free of tumour., 5 years|Disease Free Survival, Disease Free Survival is defined as the delay between date of inclusion and tumour relapse (local, regional, or distant) or death from any cause, whichever occurs first., 5 years|Overall Survival, Overall Survival is defined as the delay between the date of inclusion and the date of death, from any cause., 2 years|Overall Survival, Overall Survival is defined as the delay between the date of inclusion and the date of death, from any cause., 5 years|Incidence of Treatment-Emergent Adverse Events, The tolerance and safety will be evaluated by toxicity (acute \[\<6 months after the start of atezolizumab\] and late \[≥6 months after the start of atezolizumab\]), assessed using the NCI CTCAE v5.0, 2 years|Incidence of Treatment-Emergent Adverse Events, The tolerance and safety will be evaluated by toxicity (acute \[\<6 months after the start of atezolizumab\] and late \[≥6 months after the start of atezolizumab\]), assessed using the NCI CTCAE v5.0, 5 years|Quality of Life Core Questionnaire - Cancer Patients (QLQ-C30), Quality of life, 5 years|Quality of Life Core Questionnaire - Bladder Cancer Muscle Invasive (QLQ-BLM30), Quality of Life, 5 years|Quality of Life Core Questionnaire - Elderly Cancer Patients (QLQ-ELD14), Quality of Life, 5 years|G8 oncodage, Quality of Life, 5 years
Patients older than ≥18 years, with muscle-invasive bladder cancer unfit for radical cystectomy because of age, comorbidities, and/or patient's refusal.

This study is designed as a multicentre, single-arm phase II study.